<DOC> 
<DOCNO>1040812_business_story_3613570.utf8</DOCNO> 
<TEXT> 

The Telegraph - Calcutta : Business
 Thursday, August 12, 2004 				 Biotech boom imminent
 OUR SPECIAL CORRESPONDENT				 	 Biocon chairperson Kiran Mazumdar Shaw in Bangalore on Wednesday. (AFP)																								Bangalore, Aug. 11: The domestic biotech industry is all set to cross the $1-billion mark turnover this fiscal and emerge among the top 10 players worldwide, according to a survey conducted by the Association of Biotechnology-led Enterprises (ABLE) and Bio-Spectrum (CyberMedia).																								The sunrise industry surged ahead with a record 39 per cent growth in revenues last year at $705 million (Rs 3,265 crore), said the survey. 																								Kiran Mazumdar-Shaw, president of ABLE and chairperson of Biocon Ltd, said, The industry is expected to grow by over 40 per cent to cross the $1-billion mark in revenue during the current year. If the momentum is maintained, the industry will be able to reach its goal of $5 billion in 2010. India ranks number three in Asia and is being taken seriously globally. We will come into the top 10 (worldwide) very soon.																								According to the survey, exports contribute 55.65 per cent to the industrys revenue, while domestic business accounted for 44.35 per cent in 2003-04. This trend would continue in 2004-05, with exports likely to contribute 60 per cent of the total revenue. Of the total exports, bio-pharma accounted for 76 per cent amounting to $395 million (Rs 1,828 crore). Vaccines and statins constituted the bulk of exports, while therapeutic products dominated the domestic market, Shaw said. 
</TEXT> 
</DOC>